The adenosine A2A receptor (A2AR) has emerged as a promising target for Parkinson's disease (PD) therapy based on its ability to modulate dopaminergic neurotransmission and its remarkably discrete localization to a subset of striatal output neurons. Preclinical evidence that A2A antagonists reliably reduce motor disability without producing dyskinesias (motor complications of standard L-dopa therapy) in parkinsonian primates has led to encouraging initial clinical data on A2A antagonists in advanced PD patients already experiencing dyskinesias. However, little is known about the role of A2ARs in the maladaptive neuroplasticity underlying the development of L-dopa-induced dyskinesias (LID). We and others have demonstrated that A2AR inactivation can prevent or reverse sensitized motor responses to repeated L- dopa administration in rodent and primate models of dyskinesias. Here in response to NIH PAS-02-129 we propose to systematically investigate A2AR involvement in the maladaptive neuroplasticity of a mouse model of LID. Using complementary genetic (constitutive and brain-specific conditional knockout) and classical pharmacological approaches to adenosine (At and A2A) receptor inactivation, we will systematically pursue 3 specific aims: 1) To determine the adenosinergic (A1 and A2A) contributions to L-dopa sensitization in hemiparkinsonian (6-OHDA-lesioned) mice. 2) To determine whether A2A antagonists reduce L-dopa- induced behavioral sensitization by preventing its induction, maintenance and/or expression. 3) To explore how the A2AR interacts with its dopaminergic and heteromeric GPCR partners (D1, D2 and mGluS receptors) in modulating L-dopa sensitization. We will also assess the role of adenosine receptors in molecular adaptations linked to dyskinesias, including changes in striatal expression of dynorphin, enkephalin and the A2AR itself. Relevance: In addition to providing fundamental insights into adenosine neurobiology, the proposal is designed to yield practical knowledge of adenosine receptor function in a model of the dyskinesias that complicate standard antiparkinsonian treatments. The translational potential and efficiency of the project will be further enhanced by coordinating its ongoing findings with parallel non-human primate and clinical programs currently pursuing the therapeutic benefits of A2A antagonists for PD. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS054978-03
Application #
7433706
Study Section
Clinical Neuroscience and Disease Study Section (CND)
Program Officer
Sieber, Beth-Anne
Project Start
2006-04-01
Project End
2011-03-31
Budget Start
2008-04-01
Budget End
2009-03-31
Support Year
3
Fiscal Year
2008
Total Cost
$360,795
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Crotty, Grace F; Ascherio, Alberto; Schwarzschild, Michael A (2017) Targeting urate to reduce oxidative stress in Parkinson disease. Exp Neurol 298:210-224
Kim, Helena K; Mendonça, Karina M; Howson, Patrick A et al. (2015) The link between mitochondrial complex I and brain-derived neurotrophic factor in SH-SY5Y cells--The potential of JNX1001 as a therapeutic agent. Eur J Pharmacol 764:379-84
Wills, Anne-Marie A; Eberly, Shirley; Tennis, Marsha et al. (2013) Caffeine consumption and risk of dyskinesia in CALM-PD. Mov Disord 28:380-3
Barkhoudarian, Melita T; Schwarzschild, Michael A (2011) Preclinical jockeying on the translational track of adenosine A2A receptors. Exp Neurol 228:160-4
Xiao, Danqing; Cassin, Jared J; Healy, Brian et al. (2011) Deletion of adenosine A? or A(?A) receptors reduces L-3,4-dihydroxyphenylalanine-induced dyskinesia in a model of Parkinson's disease. Brain Res 1367:310-8
Black, Yolanda D; Xiao, Danqing; Pellegrino, Daniela et al. (2010) Protective effect of metabotropic glutamate mGluR5 receptor elimination in a 6-hydroxydopamine model of Parkinson's disease. Neurosci Lett 486:161-5
Gao, Xiang; Schwarzschild, Michael A; O'Reilly, Eilis J et al. (2010) Restless legs syndrome and Parkinson's disease in men. Mov Disord 25:2654-7
Kachroo, Anil; Irizarry, Michael C; Schwarzschild, Michael A (2010) Caffeine protects against combined paraquat and maneb-induced dopaminergic neuron degeneration. Exp Neurol 223:657-61
Morelli, Micaela; Carta, Anna R; Kachroo, Anil et al. (2010) Pathophysiological roles for purines: adenosine, caffeine and urate. Prog Brain Res 183:183-208
Cipriani, Sara; Chen, Xiqun; Schwarzschild, Michael A (2010) Urate: a novel biomarker of Parkinson's disease risk, diagnosis and prognosis. Biomark Med 4:701-12

Showing the most recent 10 out of 21 publications